Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
ketamine

Spotlight: Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm (MacConnel, et al, 2024)

"Administering ketamine in ways that parallel psychedelic-assisted treatments—including preparatory, integration, sensory immersion, and psychotherapy sessions—could decrease PTSD symptoms meaningfully."
Michael DeMarco, PhD

by Michael DeMarco, PhD

Spotlight: Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm (MacConnel, et al, 2024)
"Intravenous ketamine in supportive environments, with hallmarks of psychedelic therapy, preceded large reductions in PTSD symptoms."

https://journals.sagepub.com/doi/10.1177/02698811241286726

See Also:

Psychedelic Therapy: Does the psychedelic experience matter?
Psychedelic medicines have been studied in the Western medical literature consistently for over 100 years, over 60 of which in the ongoing study and practice of racemic ketamine. Psychedelic experiences are described similarly and often felt as profoundly meaningful.
Psychedelic Institute of Mental Health & Family TherapyMichael DeMarco, PhD
Psychedelic Cognitive Behavioral Therapy: On Ketamine, Context and Competencies in “Assisted-Psychotherapy”
There are many tools to help a psychotherapist help clients learn to speak the language of cognitive behavioral therapy, especially tools which may help facilitate therapeutic alliance, including, but not limited to telehealth.
Psychedelic Institute of Mental Health & Family TherapyMichael DeMarco, PhD

More like this

Spotlight: "Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition (Oughli, et al, 2023)

"This pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD."

Spotlight: Toward Consensus in Psychedelic-Assisted Therapy: The Critical Role of Psychotherapeutic Support (Modesto-Lowe, et al, 2025)

"...psychotherapy is essential for the safety and efficacy of psychedelic-assisted therapy... Insight from naturalistic settings emphasizes the importance of group dynamics and context."

Spotlight: MDMA + Psychotherapy as a treatment for major depressive disorder: proof of principle study (Kvam, et al, 2025)

"There were no adverse events of special interest, and no unexpected or serious adverse events. The study met the primary objectives of safety and feasibility, and provided indications of efficacy for MDMA-AT for MDD. Further studies with a randomised design are required to confirm these findings."

Spotlight: From Anesthetic to Neuroprotector: Multi-Omics Reveals Ketamine's Previously Unexplored Neuroprotective Role in Alzheimer's Disease (Gong, et al, 2025)

"This integrative study identifies robust diagnostic biomarkers and nominates ketamine for repurposing in AD. Experimental validation of ketamine's neuroprotective effects and FIBP's role is warranted."

Spotlight: Harriet de Wit: What can we learn about behavior and brain processes by studying psychoactive drugs in humans?

"her laboratory demonstrated that MDMA enhances feelings of social connectedness during interpersonal interactions, findings that have profound implications for PTSD treatment and psychotherapy."

Spotlight: Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)

"These substances are not stand-alone medications; rather, they function as adjuncts to intensive psychotherapeutic processes. Training therapists and establishing ethical, evidence-based protocols is essential."
Mastodon Mastodon